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Introduction: rVIII-SingleChain (CSL627), a novel recombinant coagulation factor VIII (FVIII), is under
investigation in a phase I/III clinical programme (AFFINITY) for the treatment of haemophilia A. Non-clinical
studies were conducted to investigate the pharmacokinetic/pharmacodynamic proﬁle of rVIII-SingleChain in
comparison with full-length recombinant FVIII.
Materials andMethods: Binding afﬁnity of rVIII-SingleChain for vonWillebrand factorwas investigated by surface
plasmon resonance analysis. The pharmacokinetic proﬁle of rVIII-SingleChain was compared with a marketed
full-length recombinant FVIII concentrate (Advate®) in haemophilia A mice, von Willebrand factor knock-out
mice, Crl:CD (SD) rats, rabbits and cynomolgusmonkeys. Systemic FVIII activity or antigen levels were recorded.
Procoagulant activity was measured in an FeCl3-induced arterial occlusion model and by recording thrombin
generation activity (ex vivo) after administration of 200–250 IU/kg rVIII-SingleChain or full-length FVIII to
haemophilia A mice.
Results: rVIII-SingleChain displayed a high afﬁnity for von Willebrand factor (KD = 44 pM vs. 139 pM
for full-length recombinant FVIII). In all animal species tested, rVIII-SingleChain had more favourable
pharmacokinetic properties than full-length recombinant FVIII: clearance was decreased and area
under the curve and terminal half-life were enhanced vs. full-length recombinant FVIII, while in vivo
recovery and volume of distribution were equivalent. rVIII-SingleChain showed a prolonged thrombin
generation potential and prolonged procoagulant activity vs. full-length recombinant FVIII in an FeCl3-induced
arterial occlusion model.
Conclusions: rVIII-SingleChain had a higher afﬁnity for von Willebrand factor than full-length recombinant FVIII
and displayed favourable pharmacokinetic/pharmacodynamic properties in non-clinical models.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
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antibodies is still a major safety issue during factor VIII (FVIII)plasma concentration vs. time
ime; CI, conﬁdence interval; CL,
enzyme-linked immunosorbent
rate constant; KA, association
ssociation equilibrium constant;
codynamic; pd-VWF, plasma-
III, recombinant factor VIII; SD,
volume of distribution; Vinitial,
tribution at steady state; VWF,
dorfstraße 10, CH-3000 Bern,
5.
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Ltd. This is an open access articlereplacement therapy; it occurs in 15 − 30% of patients [1–3] and
can lead to a higher risk of bleeding and subsequent treatment com-
plications [4,5]. Furthermore, owing to the inherently short half-life
of FVIII (approximately 10 − 14 hours), patients who undergo a
prophylactic regimen usually require three doses per week [6]. Thus,
there is an unmet medical need for a FVIII therapy that offers reduced
potential for immunogenicity with a more convenient dosing
frequency.
Under normal conditions, approximately 95% of FVIII in circulation
is in complex with von Willebrand factor (VWF) [7]. VWF is the
physiological partner of FVIII in plasma [7] and determines its half-life
and stability, and prevents its receptor-mediated clearance in vivo [8,
9]. Indeed, the half-life of FVIII is reduced to less than 3 hours in patients
with type 3 von Willebrand disease [10]. The FVIII/VWF complex also
plays an important role in the physiological activity of FVIII and has
been shown to inﬂuence the presentation of FVIII to the immune system
[8,11,12]. For instance, administration of VWF-containing concentratesunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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FVIII in patients with haemophilia A [8,11–13]. Thus, an increased inter-
action between FVIII and VWFmay improve the stability andmolecular
integrity of FVIII in circulation and minimise the risk of antibody
development.
rVIII-SingleChain (CSL627) is a novel single-chain recombinant
coagulation FVIII (rFVIII) construct composed of covalently bonded
heavy and light chains that retain all essential binding sites [14]. Fol-
lowing activation, the rFVIIIa produced from rVIII-SingleChain is
structurally identical to that formed from two-chain rFVIII [15,16].
When produced endogenously, FVIII is processed and secreted as a
heterodimer consisting of a light chain and a heavy chain joined
with a metal ion bridge [17]. Under certain conditions, this structure
can dissociate, resulting in the formation of inactive dissociated
FVIII chains [9,18,19]. This two-chain design, although physiological
for endogenous FVIII, represents a labile conﬁguration in the
manufacturing process, which can result in the formation of inactive
dissociated FVIII chains.
Previous non-clinical studies of rVIII-SingleChain in several models
of haemophilia A have shown excellent tolerability and convincing
pharmacodynamic (PD) efﬁcacy comparable to marketed full-length
and B-domain-deleted human rFVIII [14,20,21].
The present series of studies aimed to determine the binding
afﬁnity between rVIII-SingleChain and VWF and to investigate
its pharmacokinetic (PK)/PD proﬁle in several animal species,
with a view to supporting its continued clinical development in
haemophilia A.
Materials and Methods
Study Materials
The compounds tested in this series of studies were rVIII-
SingleChain (CSL Behring, Marburg, Germany) and full-length rFVIII
(Advate®, Baxter Bioscience, Vienna, Austria). Both test materials
were used directly after reconstitution or after storage below−70 °C
(one freeze/thaw cycle).
Surface Plasmon Resonance Analysis
Binding afﬁnity between rFVIII and plasma-derived (pd)-VWF
was analysed by surface plasmon resonance using a Biacore 3000 in-
strument (GE Healthcare, Freiburg, Germany). An anti-VWF mono-
clonal antibody was immobilised through primary amines onto
CM3 sensor chips (GE Healthcare) and used as a capture surface for
reversible immobilisation of pd-VWF (prepared in house). Regenera-
tion of the chip was performed by 250 mM CaCl2 solution. Full-length
rFVIII and rVIII-SingleChain were tested on the captured VWF-
immobilised chip at concentrations of 250 − 340 RU. Four batches
of rVIII-SingleChain and four batches of full-length rFVIII were mea-
sured at ﬁve different concentrations (0.125 − 1 nM) in triplicate.
The experiments were performed at 25 °C with HBS-P buffer
(GE Healthcare) as running buffer.
All binding curves measured for the VWF–rFVIII interaction were
ﬁtted into a 1:1 Langmuir binding model to determine the association
(ka) and dissociation (kd) rate constants. The ka and kd rate constants
were calculated for every set of curves individually, and association
and dissociation equilibrium constants (KA and KD) were calculated
for each set of curves separately. Biacore BIAevaluation Software
Version 4.1 (GE Healthcare) was used for data analysis. FVIII concen-
trations were determined using the chromogenic substrate (CS)
FVIII:C activity assay (Chromogenix, Milan, Italy), standardised
using an in-house standard calibrated against the international
FVIII concentrate standard (8th International Standard Factor VIII
Concentrate, NIBSC code: 07/350). The speciﬁc activity for rVIII-
SingleChain was determined as the quotient of the CS FVIII activity(IU mL−1) and the protein concentrations, which were measured in
drug substance stage samples at an optical density of 280 − 320 nm.
The measured rVIII-SingleChain batches had a mean speciﬁc activity
of 12,000 IU mg−1. For the full-length rFVIII molecule, a speciﬁc activity
of 7000 IU mg−1 was taken as the mean of literature-based values
(4000− 10,000 IU mg−1) [22]. Molar concentrations were determined
using the molar mass of 170 kDa for rVIII-SingleChain and 250 kDa for
the full-length rFVIII molecule.
Pharmacokinetics
Animals
The PK proﬁles of rVIII-SingleChain and full-length rFVIII were deter-
mined following a single intravenous injection to FVIII knock-out (KO)
mice (100 IU kg−1; Charles River Laboratories, Kisslegg, Germany)
[23], VWF KO mice (100 IU kg−1; Charles River Laboratories) [24],
Crl:CD (SD) rats (400 IU kg−1; Charles River Laboratories), Chinchilla
Bastard rabbits (150 IU kg−1; Bauer, Neuental, Germany) and
cynomolgus monkeys (Macaca fascicularis) (250 IU kg−1; Huntingdon
Life Sciences, Huntingdon, UK). Test animals were dosed according to
a CS FVIII assay system for rVIII-SingleChain (FVIII:C; Chromogenix)
and according to labelling for the comparator. Plasma samples were
drawn predose (monkeys and rabbits) and at various timepoints after
treatment until 72 hours in haemophilia A mice (n= 5 per timepoint),
48 hours in rats (n = 3 per timepoint), 72 hours in rabbits (n = 3 for
full-length rFVIII, n = 4 for rVIII-SingleChain) and 24 hours in VWF
KO mice (n = 6 per timepoint) and monkeys (n = 2 for full-length
rFVIII, n = 10 for rVIII-SingleChain). Blood samples from all species
were immediately processed in 10% citrate (9:1 mixing ratio,
3.13% w/v) for mice and monkeys and 20% citrate (8:2 mixing
ratio, 3.13% w/v) for rats and rabbits.
Pharmacokinetic Analysis
PK analysis was performed using WinNonlin version 6.0 (Pharsight,
St Louis, Missouri, USA) and FUNCALC version 2 (Prolytic GmbH,
Frankfurt am Main, Germany) software. In mice and monkeys, plasma
levels of FVIII were determined by measuring CS FVIII activity (FVIII:C
chromogenic assay, Chromogenix). In rabbits and rats, antigen determi-
nation of FVIII levels was undertaken by enzyme-linked immunosor-
bent assay (ELISA) (rats: Asserachrom Stago, S.A.S., France; rabbits:
polyclonal afﬁnity puriﬁed anti-FVIII:C immunoglobulin G, Cedarlane
Hornby, Ontario, Canada). PK parameters were determined for the
average FVIII plasma concentration vs. time curve of each group by
non-compartmental methods in FVIII KO mice, rats and rabbits. Com-
partmental models were used in VWF KO mice (one compartment)
and monkeys (two compartments) to estimate and adjust for endog-
enous FVIII activity. Further details of the PK analysis can be found in
the Supporting information.
Statistical Analysis
All statistical analyses were conducted with SAS® version 9.2 (SAS
Institute Inc., Cary, North Carolina, USA). Geometric and arithmetic
means, and standard deviations (SDs) were calculated.
In the studies in haemophilia A and VWFKOmice, the bioavailability
of rVIII-SingleChain was compared with that of full-length rFVIII by
calculating the ratio of the areas under the observed average plasma
concentration vs. time curves (AUCs), i.e., without employing extrapola-
tion. Mixed analysis of variance models was used to calculate p-values
and conﬁdence intervals (CIs). Arterial occlusion rates were analysed
in a linear mixed logistic regression model with treatment group and
log(time) as covariates and animal as random effect.
Thrombin Generation Assay (ex vivo)
Haemophilia A mice were treated with rVIII-SingleChain or full-
length rFVIII with a single intravenous administration of 250 IU kg−1
Table 1
Mean (standard deviation) kinetic parameters and equilibrium constants of the binding
of rVIII-SingleChain and full-length rFVIII (Advate®) to plasma-derived von Willebrand
factor. rVIII-SingleChain was from four different development lots and full-length rFVIII
(Advate®) was from four commercially available lots. Each lot was measured in triplicate.
Mean (±standard
deviation)
rVIII-SingleChain
(n = 4)
Full-length rFVIII
(n = 4)
ka (M−1 s−1) 5.36 × 106 (±1.65 × 106) 2.12 × 106 (±1.25 × 105)
kd (s−1) 2.18 × 10−4 (±4.06 × 10−6) 2.92 × 10−4 (±6.47 × 10−6)
KA (M−1) 24.7 × 109 (±7.84 × 109) 7.27 × 109 (±5.34 × 108)
KD (pM) 43.64 (±12.65) 139.42 (±11.59)
Abbreviation: FVIII, factor VIII; ka, association rate constant; KA, equilibrium association
constant; kd, dissociation rate constant; KD, equilibrium dissociation constant; rFVIII,
recombinant factor VIII.
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different timepoints (Days 1 − 8). Blood samples were processed in
10% citrate plasma (9:1 mixing ratio, 3.13% w/v) and stored at room
temperature until centrifugation. Samples were centrifuged at 3000 g
in a Megafuge® 1.0R centrifuge ﬁtted with a swing-out rotor #2704
(Thermo Scientiﬁc Heraeus, Langenselbold, Germany) for 10 minutes
at room temperature. Plasma was then pipetted off and stored at
approximately −70 °C until analysis. The thrombin generation
assay was performed by calibrated automated thrombography
(CAT, Thrombinoscope, Maastricht, The Netherlands) after intrinsic
activation in the presence of phospholipids (Rossix, Mölndal,
Sweden)/Pathromtin® SL (Siemens Healthcare Diagnostics Products
GmbH, Marburg, Germany). Thrombin peak levels were recorded
and the average AUC of peak thrombin levels for Days 1− 8 calculat-
ed by the linear trapezoidal rule. The AUCs of the two FVIII products
were compared using an approximate F-test for the difference in
AUC in a linear model with variable variances per timepoint and
treatment group, resulting in an estimated time until peak levels of
thrombin dropped below a deﬁned limit ranging between 50 and
250 nM.FeCl3-induced Arterial Occlusion
Arterial occlusion was induced in haemophilia A mice by placing a
patch of ﬁlter paper saturated with 10% FeCl3 on the carotid artery for
3 minutes. Blood ﬂowwas assessed for 40 minutes using a perivascular
ﬂow module TS420 and perivascular ﬂow probes (Transonic System
Inc., Ithaca, New York, USA) to monitor thrombotic occlusion. Mice
were dosed with 200 IU kg−1 of rVIII-SingleChain or full-length rFVIII
according to labelled FVIII activity at 24, 32, 40, 48, 54 and 64 hours
before induction of thrombosis. A vehicle (buffer)-treated group served
as control.0
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Fig. 1. Binding curves of: (A) rVIII-SingleChain and (B) full-length rFVIII (Advate®) to
plasma-derived von Willebrand factor. rFVIII concentrations from 0.125 nM to 1 nM
were measured. rFVIII, recombinant factor VIII; RU, relative units.Results
Surface Plasmon Resonance Analysis
Surface plasmon resonance analysis showed that rVIII-SingleChain
had a greater afﬁnity for VWF than full-length rFVIII (Fig. 1). The
means and SDs of the different lots are shown in Table 1.
The dissociation equilibrium constant of rVIII-SingleChain and
pd-VWF was determined at 44 pM; for full-length rFVIII, the dissoci-
ation equilibrium constant was 139 pM. Thus, the afﬁnity of rVIII-
SingleChain for pd-VWF was 3-fold higher than the afﬁnity of the
full-length rFVIII molecule, mainly originating from a higher ka.
Pharmacokinetics
Haemophilia A Mice
The PK parameters of rVIII-SingleChain vs. full-length rFVIII in
haemophilia A mice are given (Table 2 and Fig. 2A). There was an
approximately 2-fold enhancement of AUC up to the last quantiﬁable
sampling time (AUC0-last) with rVIII-SingleChain vs. full-length
rFVIII. Likewise, mean residence time (MRT) and terminal half-life
(t1/2β) were approximately 2-fold higher with rVIII-SingleChain.
AUC0-last and t1/2β results obtained after rVIII-SingleChain treatment
were signiﬁcantly higher compared with full-length rFVIII, with an
AUC0-last ratio of 1.97 (90% CI, 1.7–2.3; p b 0.0001) and a t1/2β ratio
of 1.65 (90% CI, 1.11–2.70; p= 0.036). In accordancewith these chang-
es, clearance (CL) of rVIII-SingleChain was lower than with full-length
rFVIII. Both volume of distribution at steady state (Vss) and maximum
plasma concentration (Cmax) were similar between treatment groups.
VWF KO Mice
The AUC0-last and t1/2β of both rVIII-SingleChain and full-length rFVIII
decreased by a factor of approximately 30 in VWF KO mice compared
with haemophilia A mice (Table 2 and Fig. 2B). However, the ratios of
PK parameters for rVIII-SingleChain compared with full-length rFVIII
in VWF KO mice were similar to those observed in haemophilia A
mice. The estimated AUC0-last ratio for rVIII-SingleChain:full-length
rFVIII was 2.04 (90% CI, 1.47–2.99; p = 0.001) in VWF KO mice. This
was despite the slightly higher in vivo recovery for rVIII-SingleChain
vs. full-length rFVIII in the initial phase after administration in VWF
KO mice (Table 2 and Fig. 2B) compared with similar in vivo recovery
for both molecules in haemophilia A mice.
Rats
The PK parameters of rVIII-SingleChain and full-length rFVIII in Crl:
CD (SD) rats are given (Table 2 and Fig. 2C). AUC0-last was increased ap-
proximately 6-fold with rVIII-SingleChain compared with full-length
rFVIII. Similarly, t1/2β and MRT were approximately 2- to 3-fold higher
and CL was more than 5-fold lower compared with full-length rFVIII.
Cmax was marginally higher with rVIII-SingleChain than full-length
rFVIII, while Vss was more than 2-fold lower.
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The PK parameters of rVIII-SingleChain and full-length rFVIII in
rabbits are given (Table 2). AUC0-last was increased almost 4-fold with
rVIII-SingleChain compared with full-length rFVIII. Similarly, t1/2β was
more than 2-fold higher, MRT was more than 2-fold higher and CL
wasmore than 2-fold lower with rVIII-SingleChain vs. full-length rFVIII.
Cmax and Vss were similar between treatment groups.
Cynomolgus Monkeys
Plasma levels of FVIII declined from amaximum at the ﬁrst sampling
time in an apparent bi-exponential manner, with a t1/2β of 10.8 hours
(range: 6.8− 15.6 hours) for rVIII-SingleChain and 6.9 hours (range:
6.5 − 7.3 hours) for full-length rFVIII, and an MRT of 15.3 hours and
9.2 hours, respectively (Table 2 and Fig. 2D). Mean AUC0-last following
administration of rVIII-SingleChain was approximately 1.5-fold higher
than that after administration of full-length rFVIII and CL was approxi-
mately 2-fold lower. In vivo recovery and Vss appeared similar between
groups. Both treatments were well tolerated and there were no adverse
clinical signs, reactions to treatment or treatment-associated injection-
site reactions.
The PK proﬁle was dose proportional over the range of 50 −
1500 IU/kg and PK parameters derived from all other dose groups
(i.e. besides the 250 IU/kg group) support the favourable PK properties.
Median t1/2β of rVIII-SingleChain calculated from 48 monkeys in two
PK and two Good Laboratory Practice-compliant toxicology studies
[21] was 10.4 hours and median clearance was 2.64 mL h−1 kg−1
(data not shown).
Thrombin Generation Assay
In haemophilia A mice, rVIII-SingleChain showed favourable
haemostatic activity compared with full-length rFVIII, as indicated by
the longer duration (average of 20 hours) for the thrombin peak levels
to drop below each limit between 50 and 250 nM (Fig. 3). When
assessing the area under the peak curve between Days 1 and 8, the
thrombin generation activity of rVIII-SingleChain was also signiﬁcantly
higher than full-length rFVIII (estimated ratio 1.26, 90% CI, 1.14–1.39;
p[AUCTGA Peak ratio = 1] = 0.0002).
FeCl3-induced Arterial Occlusion
Similarly, higher and longer PD effects of rVIII-SingleChain were
evident compared with full-length rFVIII in an FeCl3-induced arterial
occlusion model in haemophilia A mice over 64 hours (Fig. 4). In both
treatment groups the occlusion rates decreased with time, indicating
the loss of FVIII activity over time. On average, the time to reach a
particular occlusion rate was approximately 29 hours later in the
rVIII-SingleChain-treated mice than in the mice treated with full-
length rFVIII, however, the difference was not signiﬁcant (p= 0.13).
Discussion
The present series of non-clinical studies assessed the binding afﬁn-
ity of rVIII-SingleChain to VWF and investigated its PK and PD proﬁles in
animals. rVIII-SingleChain showed improved binding afﬁnity for VWF
compared with full-length rFVIII in haemophilia A mice. Furthermore,
rVIII-SingleChain had a favourable PK proﬁle in four non-clinical animal
species vs. marketed full-length rFVIII and prolonged procoagulant
effects in haemophilia A mice.
The binding of VWF to FVIII in plasma plays a vital role in its stability,
half-life and presentation to the immune system [8,11,12]. In the present
study, a 3-fold increase in the binding afﬁnity of rVIII-SingleChain for
VWF, resulting in more rapid and stronger binding to VWF vs. full-
length rFVIII, represents a favourable ﬁnding in comparison with other
rFVIII products currently under development. Similar studies with
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increases, respectively, in binding afﬁnity vs. full-length rFVIII [25,26].
It appears that the enhanced binding of rVIII-SingleChain to
VWF may contribute to its beneﬁcial PK characteristics. The half-life of
rVIII-SingleChain was, depending on the animal model, approximately
2-fold greater than full-length rFVIII and CL was approximately 2-fold
lower. Moreover, the overall PK properties of rVIII-SingleChain and
full-length rFVIII were markedly different in haemophilia A mice
compared with VWF KO mice. In VWF KO mice, the AUC and half-life
were approximately 30 times lower, and accordingly clearance was
higher compared with haemophilia A mice. This emphasises the
importance of strong binding of FVIII to VWF for improving the phar-
macokinetic properties of FVIII. Additionally, as rVIII-SingleChain
showed similarly beneﬁcial pharmacokinetic properties in VWF KO
mice compared with full-length rFVIII, it may be assumed that other
features, such as the intrinsic molecular stability and thus structural
integrity of rVIII-SingleChain, also contribute to its favourable
properties.
Owing to the short half-life of FVIII, current prophylaxis regimens
for haemophilia A typically require injections three times per week to
maintain a sufﬁcient level of circulating clotting factor. The inconve-
nience of three times weekly dosing is a signiﬁcant burden to people
with haemophilia A. The favourable PK of rVIII-SingleChain may
therefore offer the potential for more convenient dosing schedules,
a hypothesis that needs to be conﬁrmed in future human studies.
The PKproperties of rVIII-SingleChain in several animal species com-
pare favourably with several extended half-life products currently
under development, which employ strategies such as PEGylation and
fusion protein technology to reduce the required dosing frequency.
For instance, in studies in haemophilia A mice, the t1/2β of rFVIIIFc was
13.7 hours [27], PEGylated B-domain deleted-rFVIII was 13.6 hours
[28], glycoPEGylated rFVIII (N8-GP) was 14 hours [29] and PEGylated
rFVIII (BAX 855) was 5.9 hours [30] compared with 15.9 hours for
rVIII-SingleChain. Corresponding studies in rabbits, rats and monkeysalso show similar half-lives as rVIII-SingleChain for PEGylated
B-domain deleted-rFVIII [28], glycoPEGylated rFVIII (N8-GP) [29] and
PEGylated rFVIII (BAX 855) [30]. Interestingly, comparison of half-life
values obtained using different methods to determine plasma FVIII
levels suggests that ELISA-based analysis tends to result in a longer
half-life than activity-based assays. This observation has been reported
for PEGylated FIX (N9-GP) [31] and PEGylated rFVIII (BAX 855) [30] in
non-clinical species. Furthermore, ELISA analysis of N8-GP plasma
levels in monkeys revealed a notably longer half-life (18 hours) [29]
than for BAX 855 (9.4 hours) [30] and rVIII-SingleChain (10.8 hours),
which were derived by FVIII chromogenic activity. In accordance
with its favourable t1/2β, CL of rVIII-SingleChain in non-clinical
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molecules [27,29,30].
Interestingly, regardless of the method of extension, the half-life
of modiﬁed rFVIII variants appears to be maximally twice as long as
wild-type FVIII in a variety of non-clinical animal models. This suggests
that similar to the human situation, the half-life of FVIII in animals is
predominantly determined by the elimination half-life of its physiolog-
ical partner VWF. Intriguingly, among animal species, monkeys mimic
human conditions in terms of the dependency of FVIII/VWF half-life
on intrinsic variability factors for VWF half-life (e.g., ABO blood group
[32] and glycosylation). To this end, the PK of rVIII-SingleChain in
monkeys may be most relevant to its clinical PK, which is currently
under investigation in the AFFINITY clinical trial programme.
The improved PKof rVIII-SingleChainwere reﬂected in the improved
PD vs. full-length rFVIII. In haemophilia A mice rVIII-SingleChain
showed favourable haemostatic activity in a thrombin generation
assay and prolonged procoagulant activity in FeCl3-induced arterial
occlusion. The arterial occlusion model exhibits lower variability and
better sensitivity at lower FVIII activity levels than the tail-cut bleeding
model [33,34], which allows measurement of smaller, but still distin-
guishable, differences in procoagulant activity. The arterial occlusion
model was therefore considered themore suitablemodel for evaluating
potential differences in procoagulant activity between rVIII-SingleChain
and full-length rFVIII, particularly at the advanced time points
investigated (up to 64 hours).
This non-clinical programme indicates favourable PK and PD
for rVIII-SingleChain compared with full-length rFVIII. The ongoing
AFFINITY clinical trial programme (phase I/III) will assess the PK, safety,
immunogenicity and efﬁcacy of rVIII-SingleChain in patients with
haemophilia A.
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